Arthur Hayes returns to the highlight with a major transfer: becoming a member of the board and buying a considerable stake in an organization lively within the stem cell sector, with the declared objective of tapping into the longevity pattern that draws capital even from the crypto world. The change of state of affairs would come after a supposed presidential pardon that may have eased operational constraints and redefined his public profile following the well-known occasions associated to BitMEX.
Based on the information collected by the editorial group, primarily based on analysis in public information and company communications obtainable as of August 21, 2025, there may be nonetheless no official assertion explicitly naming the corporate concerned or the precise share of the stake. The business analysts we consulted word that it’s comparatively frequent for crypto household places of work to undertake diversify-in-healthcare methods earlier than formal bulletins to the media. In our evaluation of public filings (e.g., SEC’s EDGAR database) and registrations in international jurisdictions, no public affirmation paperwork have but emerged concerning the formal entry into the board.
From buying and selling to biomedicine: what Arthur Hayes is doing
The co-founder of BitMEX is reportedly reallocating a part of the capital in direction of regenerative medication, taking over a governance function and buying a stake in an organization that gives stem cell-based therapies. It must be famous that the knowledge remains to be partial. Based on some rumors, Arthur Hayes has been attending clinics in Mexico and Thailand for over a yr, exploring protocols geared toward enhancing metabolic well being and stopping ageing.
What we all know thus far (and what stays to be clarified)
- Function: presence on the board of administrators of the corporate (firm identify to be verified);
- Participation: funding described as “related” (official percentages usually are not obtainable);
- Direct expertise: it’s rumored that Hayes has obtained therapies on the similar facility the place he invests, info but to be confirmed with official sources;
- Declared goal: intention to increase well being in previous age relatively than “prolonging the years” at any value.
Why crypto capital seems to be at longevity
The wealth created within the digital ecosystem is observing with rising curiosity excessive asymmetry verticals between danger and influence. Biogerontology falls into this class. On this context, crypto finance is accustomed to speedy innovation cycles: a mindset that mixes with frontier biotech.
- Vitalik Buterin has supported tasks and foundations dedicated to the research of ageing, together with the SENS Analysis Basis;
- Brian Armstrong is among the many supporters of NewLimit, a startup targeted on mobile reprogramming for longevity;
- Balaji Srinivasan is understood for his views on the mixing between digital know-how and rising sectors, though the reference to his participation in firms like Counsyl (now a part of Myriad Genetics) is just not confirmed.
- Household workplace crypto: they assist conventional enterprise capitalists in early-stage rounds and pre-clinical investments in ATMP.
Impact of the alleged presidential pardon: extra freedom of maneuver on investments
The alleged grazia presidenziale would have eliminated some procedural boundaries associated to earlier judicial issues, permitting Hayes to simply accept public appointments and current himself as an lively investor. An attention-grabbing facet is the potential enchancment in entry to deal‑movement, regulated networks, and sooner decision-making processes. Nevertheless, the conventional verifiche di conformità required for governance roles within the healthcare sector stay.
Crypto sure, however not solely: Maelstrom stays targeted on digital
Regardless of the rising consideration in direction of biotech, Hayes doesn’t abandon the perimeter of cryptocurrencies. The household workplace, Maelstrom, continues to assist Bitcoin builders and firms with tokens on the stability sheet, sustaining a barbell technique that mixes digital belongings and investments in life sciences.
Clinics overseas and cell remedy: alternatives and dangers
The deal with Messico and Thailandia signifies the seek for environments with typically extra permissive laws in comparison with the USA and Europe. This could speed up innovation, nevertheless it additionally requires better transparency, traceability, and strong scientific knowledge.
Regulatory framework comparability
- USA (FDA): the Meals and Drug Administration signifies that many stem cell therapies usually are not accepted and should current dangers; see the buyer alert from the FDA.
- EU (EMA): superior therapies fall into the ATMP class and require centralized authorization; the overview from the EMA is accessible.
- Mexico (COFEPRIS): the regulator COFEPRIS has beforehand recalled unauthorized affords of mobile therapies.
- Thailand (Thai FDA): the Thai FDA regulates organic merchandise by requiring registrations and trials for therapeutic indications.
For buyers, the message stays clear: innovation and first-mover benefit can open alternatives, however regulatory, scientific, and reputational dangers stay excessive. With out sturdy scientific proof, returns might be delayed or, merely, not materialize.
Important Timeline
- In recent times: authorized proceedings associated to BitMEX and associated restrictions;
- Lately: alleged granting of a presidential pardon that may have eliminated constraints for public appointments;
- Ongoing: Hayes’ entry into the board and funding in an organization lively in stem cells with operations in Mexico/Thailand;
- In parallel: Maelstrom continues with grants to builders and participation in crypto-native tasks.
Affect available on the market: extra capital, extra competitors, extra due diligence
The inflow of crypto capital into longevity biotech might compress improvement occasions, shifting the main focus to managed trials, measurable scientific endpoints, and stricter governance. Competitors for expertise is rising, and the price of accessing samples and GMP infrastructure is growing. A fragile level stays open: who will be capable of afford costly and, in lots of instances, nonetheless experimental therapies?
What’s confirmed vs what is just not verified
What’s confirmed
- Hayes’s curiosity in longevity and regenerative medication;
- The upkeep of crypto belongings by means of Maelstrom;
- The stringent regulatory context in USA/UE for mobile therapies, highlighted by the buyer alert from the FDA and EMA laws;
- The involvement of well-known crypto buyers, similar to Buterin and Armstrong, within the area of longevity.
What is just not verified
- The identify of the stem cell firm wherein Hayes invests and the documentation associated to his entry into the board (press launch, submitting, or official registration);
- The precise entity of the participation (share or vary) and the exact date of the operation;
- Direct statements from Hayes with verifiable sources (interview, official publish, or public transcript);
- Medical particulars on the therapies obtained (indications, protocols, revealed proof of efficacy and security).
The general image
Hayes’s selection indicators a broader dynamic: capital originating within the crypto sector is exploring new frontiers of healthcare innovation. An attention-grabbing facet is the convergence between digital finance and biotech, which may speed up improvement however requires rigorous scientific trials, regulatory oversight, and a spotlight to fairness of entry. Solely on this method can the race for longevity transfer from narrative to concrete, measurable, and, above all, replicable outcomes.
Sources and insights
- https://www.fda.gov/shoppers/consumer-updates/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
- https://stemcells.nih.gov/
- https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview
- https://www.gob.mx/cofepris
- https://www.fda.moph.go.th/
- https://sens.org
- https://www.newlimit.com/
- https://www.sec.gov/edgar/search/
